Clinical data | |
---|---|
Trade names | Arsobal[1] |
Other names | Mel B, Melarsen Oxide-BAL[2] |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | IV |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 35 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.007.086 |
Chemical and physical data | |
Formula | C12H15AsN6OS2 |
Molar mass | 398.33 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis).[1] It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved.[1] For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred.[1] It is effective in about 95% of people.[3] It is given by injection into a vein.[2]
Melarsoprol has a high number of side effects.[4] Common side effects include brain dysfunction, numbness, rashes, and kidney and liver problems.[2] About 1-5% of people die during treatment, although this is tolerated due to sleeping sickness itself having a practically 100% mortality rate when untreated.[3] In those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cell breakdown may occur.[2] It has not been studied in pregnancy.[2] It works by blocking pyruvate kinase, an enzyme required for aerobic metabolism by the parasite.[2]
Melarsoprol has been used medically since 1949.[1] It is on the World Health Organization's List of Essential Medicines.[5] In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization.[4] It is not commercially available in Canada or the United States.[2] In the United States, it may be obtained from the Centers for Disease Control and Prevention, while in Canada it is available from Health Canada.[1][2]